Article
Novel epidermal growth factor receptor mutation-specific antibodies for non-small cell lung cancer: immunohistochemistry as a possible screening method for epidermal growth factor receptor mutations.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer - 1 Oct 2010
Kato Yasufumi, Peled Nir, Wynes Murry W, Yoshida Koichi, Pardo Marta, Mascaux Celine, Ohira Tatsuo, Tsuboi Masahiro, Matsubayashi Jun, Nagao Toshitaka, Ikeda Norihiko, Hirsch Fred R
Abstract excerpt
BACKGROUND: Epidermal growth factor receptor (EGFR) mutations in non-small cell lung cancer (NSCLC) predict better outcome to EGFR tyrosine kinase inhibitors. The most common mutations are exon 19 deletions (most frequently E746-A750) and L858R point mutation in exon 21. Here, we evaluated the accuracy of novel EGFR mutation-specific antibodies in a Japanese cohort with NSCLC and compared with direct DNA...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.